Pharma

Your Article Summary

See Latest Articles

FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
Cell Therapeutics, 09/04/09

Cell Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted and has filed for review the Company's New Drug Application for pixantrone as treatment for relapsed or refractory aggressive non–Hodgkin's lymphoma. A Prescription Drug User Fee Act date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR
Abbott, 12/11/09

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

 See all of Drug/Product Approvals